利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.014 秒)

    PROCÉDÉ POUR DÉTERMINER LE PRONOSTIC DE SURVIE D'UN PATIENT ATTEINT D'UN CANCER DU PANCRÉAS
    4.
    发明公开
    PROCÉDÉ POUR DÉTERMINER LE PRONOSTIC DE SURVIE D'UN PATIENT ATTEINT D'UN CANCER DU PANCRÉAS 审中-公开
    PROCÉDÉPOURDÉTERMINERLE PRONOSTIC DE SURVIE D'UN患者ATTEINT D'UN CANCER DUPANCRÉAS

    公开(公告)号：EP3183363A2

    公开(公告)日：2017-06-28

    申请号：EP15759902.8

    申请日：2015-08-13

    申请人： ACOBIOM

    发明人： PIQUEMAL, David

    IPC分类号： C12Q1/68 ,  G01N33/574 ,  G01N33/68

    摘要： The present invention relates to pancreatic cancer, and more particularly to the survival prognosis of a patient suffering from pancreatic cancer. The invention also aims to determine the suitability of said patient to receive a treatment for pancreatic cancer, in particular a treatment with gemcitabine. The invention also concerns a method for monitoring the effectiveness of a treatment for pancreatic cancer, and advantageously a treatment with gemcitabine, by implementing the method.

    摘要翻译： 本发明涉及胰腺癌，并且更具体地涉及患有胰腺癌的患者的存活预后。 本发明还旨在确定所述患者接受胰腺癌治疗的适合性，特别是用吉西他滨治疗。 本发明还涉及一种通过实施该方法来监测胰腺癌治疗效果并且有利地用吉西他滨治疗的方法。

    USE OF MASITINIB FOR TREATMENT OF CANCER IN PATIENT SUBPOPULATIONS IDENTIFIED USING PREDICTOR FACTORS
    7.
    发明公开
    USE OF MASITINIB FOR TREATMENT OF CANCER IN PATIENT SUBPOPULATIONS IDENTIFIED USING PREDICTOR FACTORS 有权
    马赛替尼对癌症的使用PRÄDIKTORFAKTOREN治疗中的应用识别的患者亚群

    公开(公告)号：EP2903616A1

    公开(公告)日：2015-08-12

    申请号：EP13773731.8

    申请日：2013-10-04

    申请人： AB Science

    发明人： MOUSSY, Alain ,  KINET, Jean-Pierre ,  PIQUEMAL, David

    IPC分类号： A61K31/496 ,  A61K31/7068 ,  A61P35/00

    CPC分类号： A61K31/496 ,  A61K31/7068 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  A61K2300/00

    摘要： The present invention relates to a method for treating patients afflicted with cancer, wherein said patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that comprises a therapeutically effective amount. The present invention also relates to methods for predicting therapeutic response to said treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity. The second method is based upon gene expression predictive biomarkers assessed via RNA expression in peripheral blood cell samples collected prior to treatment with a compound of the invention (i.e. a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, especially masitinib). Advantageously, the present invention relates to a method for treating patients afflicted with pancreatic cancer wherein said patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and in particular masitinib, optionally in combination with at least one antineoplastic agent, and in particular gemcitabine.

    摘要翻译： 一种用于治疗患有癌症的患者，worin患者方法治疗与包括酪氨酸激酶抑制剂，肥大细胞抑制剂或c-kit抑制剂，特别是马赛替尼的化合物，任选地与至少一种抗肿瘤剂。 所述酪氨酸激酶抑制剂，肥大细胞抑制剂或c-kit抑制剂，和任选的至少一种抗肿瘤剂，施用的剂量方案做了包括治疗有效量。 这样描述的是用于预测在给定的患者对治疗的治疗反应，因此鉴定基于合成预测因素适用患者亚群方法; 有时通过向称为生物标志物。 一个方法是基于疼痛强度的临床标志物。 另一种方法是基于通过RNA表达与化合物治疗之前收集外周血细胞样品中预测评定基因表达的生物标志物，从而所有被用于治疗患有胰腺癌折磨的患者。

    USE OF MASITINIB IN COMBINATION WITH GEMCITABINE FOR TREATING A SUBGROUP OF PATIENTS SUFFERING FROM PANCREATIC CANCER
    9.
    发明授权
    USE OF MASITINIB IN COMBINATION WITH GEMCITABINE FOR TREATING A SUBGROUP OF PATIENTS SUFFERING FROM PANCREATIC CANCER 有权
    美西他滨联合用于治疗胰腺癌患者亚组的胰岛素抵抗

    公开(公告)号：EP2903616B8

    公开(公告)日：2018-02-07

    申请号：EP13773731.8

    申请日：2013-10-04

    申请人： AB Science

    发明人： MOUSSY, Alain ,  KINET, Jean-Pierre ,  PIQUEMAL, David

    IPC分类号： A61K31/496 ,  A61K31/7068 ,  A61P35/00

    CPC分类号： A61K31/496 ,  A61K31/7068 ,  A61K45/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  A61K2300/00

    摘要： A method for treating patients afflicted with cancer, wherein the patients are treated with a compound including tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that includes a therapeutically effective amount. Also described are methods for predicting therapeutic response to the treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity. Another method is based upon gene expression predictive biomarkers assessed via RNA expression in peripheral blood cell samples collected prior to treatment with the compound, which is also used for treating patients afflicted with pancreatic cancer.